Insulin lispro biosimilar (Wockhardt)

赖脯胰岛素生物类似药 (Wockhardt)

Report date: 2024/10/25 20:00:29

Base Information

Drug NameInsulin lispro biosimilar (Wockhardt)
Drug Alias NameInsulin lispro biphasic biosimilar - Wockhardt
ClassificationBiologics > Protein drugs > Recombinant protein > Recombinant hormoneBiologics > Biosimilar
Mechanisms of ActionInsulin receptor agonists
TargetsInsulin receptor
Therapy Area/IndicationsDiabetes Mellitus, Type 1
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusDiscontinued (Phase 3 Clinical)
Highest Status in ChinaN/A
Originator CompaniesWockhardt Ltd
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesWockhardt Ltd
Active IndicationsN/A
Inactive IndicationsDiabetes Mellitus, Type 1

Other Information

ATC CodeN/A
Related LinksN/A